{"public_id":"cl_c400ccce62f3607804fe97e57fc733f4","status":"active","superseded_by_public_id":null,"corpus_id":25487676,"text":"Persistent anal infection with HPV-6, 11, 16, or 18 was reduced by 59.4% in the intention-to-treat population and by 94.9% in the per-protocol efficacy population.","confidence":0.97,"paper":{"corpus_id":25487676,"title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.","url":"https://sah.borca.ai/papers/25487676"},"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["review"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.97,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_43f383c3cf1a8a9c3034ddfc53bbf873","name":"HPV-6, 11, 16, or 18 infection","description":"Infection with one of the four human papillomavirus types targeted by the quadrivalent vaccine.","types":["infection"],"url":"https://sah.borca.ai/concepts/co_43f383c3cf1a8a9c3034ddfc53bbf873"},{"public_id":"co_91f53885e4c1ea15d8800cb5d8a64bf4","name":"intention-to-treat population","description":"An efficacy analysis population used to estimate vaccine effects among randomized participants.","types":["analysis population"],"url":"https://sah.borca.ai/concepts/co_91f53885e4c1ea15d8800cb5d8a64bf4"},{"public_id":"co_c1bf81a3ee5c827492fb8e6ac8a663c2","name":"persistent anal infection","description":"Ongoing anal infection with HPV types assessed as an infection endpoint in the trial.","types":["infection","outcome"],"url":"https://sah.borca.ai/concepts/co_c1bf81a3ee5c827492fb8e6ac8a663c2"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_c400ccce62f3607804fe97e57fc733f4"}